Item List

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 Gene Therapy in Adults with Macular Neovascularization

A Phase 3 Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) Gene Therapy in Participants With wet AMD

A Phase 3 Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients with Geographic Atrophy (GA)

A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (DME)
To be eligible for the study, participants must be at least 18 years of age or older, have been diagnosed with Type 1/2 Diabetes and DME associated with Diabetic Retinopathy, and willing to allow Aqueous Humor collection

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/​Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World
Safety, Tolerability and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with
Geographic Atrophy Secondary to Age-Related Macular Degeneration

Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related

Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of oral BI 1584862

A Phase 3 Study of EYP-1901 (Tyrosine Kinase Inhibitor) in Subjects With Wet Age-Related Macular Degeneration (wAMD)

A Phase 3 Study of EYP-1901 (Tyrosine Kinase Inhibitor) in Subjects With Wet Age-Related Macular Degeneration (wAMD)

The Natural History Observation Registry (NHOR) is a world-wide registry of individuals with Macular Telangiectasia type 2, and their family members.